Details for New Drug Application (NDA): 213001
✉ Email this page to a colleague
The generic ingredient in FOSCARNET SODIUM is foscarnet sodium. There are seven drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the foscarnet sodium profile page.
Summary for 213001
Tradename: | FOSCARNET SODIUM |
Applicant: | Gland Pharma Ltd |
Ingredient: | foscarnet sodium |
Patents: | 0 |
Pharmacology for NDA: 213001
Mechanism of Action | Chelating Activity DNA Polymerase Inhibitors |
Medical Subject Heading (MeSH) Categories for 213001
Suppliers and Packaging for NDA: 213001
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
FOSCARNET SODIUM | foscarnet sodium | INJECTABLE;INJECTION | 213001 | ANDA | Sagent Pharmaceuticals | 25021-189 | 25021-189-84 | 10 BAG in 1 CARTON (25021-189-84) / 250 mL in 1 BAG |
FOSCARNET SODIUM | foscarnet sodium | INJECTABLE;INJECTION | 213001 | ANDA | Baxter Healthcare Corporation | 43066-089 | 43066-089-10 | 10 BAG in 1 CARTON (43066-089-10) / 250 mL in 1 BAG |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 2.4GM/100ML | ||||
Approval Date: | Apr 21, 2021 | TE: | AP | RLD: | No |
Complete Access Available with Subscription